<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376752</url>
  </required_header>
  <id_info>
    <org_study_id>FEDEGYN 02 / 0410-CHIPOR</org_study_id>
    <secondary_id>2010-023035-42</secondary_id>
    <nct_id>NCT01376752</nct_id>
  </id_info>
  <brief_title>Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment</brief_title>
  <acronym>CHIPOR</acronym>
  <official_title>A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CHIPOR hypothesis is that the adjunction of platinum HIPEC in first relapsed epithelial&#xD;
      ovarian cancer is able to improve the median Overall Survival (OS) by 12 months. In that&#xD;
      hypothesis, with alpha risk of 5%, a power beta of 80%, during a 3 years period of inclusion&#xD;
      and a 3 years follow-up, the number of patients to include is 404. Taking into account a 10%&#xD;
      failure, an overall number of 444 patients is required.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient received before the surgery a second line chemotherapy, platinum-based regimen&#xD;
      with either carboplatine-paclitaxel, or carboplatine-caelyx. At the end of the six courses IV&#xD;
      chemotherapy, if the disease is still responding and if a complete cytoreductive surgery&#xD;
      seems possible, the patient is included after signed informed consent and will be operated 5&#xD;
      to 8 weeks after the last second-line chemotherapy cycle.&#xD;
&#xD;
      So, during the surgery the patient will be randomized if the complete cytoreductive surgery&#xD;
      is really done and will then receive:&#xD;
&#xD;
        -  either treatment A = maximal cytoreductive surgery without HIPEC&#xD;
&#xD;
        -  or treatment B = maximal cytoreductive surgery with HIPEC&#xD;
&#xD;
      The HIPEC will be done at the end of the surgery. At the end of cytoreductive surgery, tumor&#xD;
      residual disease must be null or very limited (Sugarbaker completeness cytoreduction: CC0 (no&#xD;
      residual)-CC1 (residual &lt; 0.25cm).&#xD;
&#xD;
      Two methods will be used for the HIPEC: Open or closed abdomen, depends on the site practice.&#xD;
      Each site will use the same method during the study for all included patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>from randomization to death (up to 4 years)</time_frame>
    <description>Follow-up of 4 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse free survival</measure>
    <time_frame>from randomization to relapse (up to 4 years)</time_frame>
    <description>Follow-up of 4 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">415</enrollment>
  <condition>Ovarian Epithelial Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>maximal cytoreductive surgery without HIPEC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participant will have a regular cytoreductive surgery without the adjunction of HIPEC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maximal cytoreductive surgery with HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will have a regular cytoreductive surgery, then the adjunction of HIPEC: hyperthermic cisplatin will be used at 75mg/m²</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Maximal cytoreductive surgery</intervention_name>
    <description>Maximal cytoreductive surgery</description>
    <arm_group_label>maximal cytoreductive surgery with HIPEC</arm_group_label>
    <arm_group_label>maximal cytoreductive surgery without HIPEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIPEC</intervention_name>
    <description>HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²</description>
    <arm_group_label>maximal cytoreductive surgery with HIPEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient age ≥ 18 years&#xD;
&#xD;
          -  Performance Status WHO &lt; 2&#xD;
&#xD;
          -  Initially treated for Epithelial Ovarian Carcinoma&#xD;
&#xD;
          -  Patient with only peritoneal relapse occurred at least 6 month from the initial&#xD;
             treatment, resectable without distant metastasis (with the exception of communicating&#xD;
             pleura effusion, sensitive to platine-based second line chemotherapy and resectable&#xD;
             lymph-nodes in the groin or retro peritoneal)&#xD;
&#xD;
          -  Platinum based second-line chemotherapy before surgery with either&#xD;
             carboplatine-paclitaxel, or carboplatine-caelyx&#xD;
&#xD;
          -  Complete cytoreductive surgery&#xD;
&#xD;
          -  The surgery has to be planned 5 to 8 weeks from the last 2nd of chemotherapy&#xD;
&#xD;
          -  No hepatic failure, bilirubin ≤ 1,5 time the Normal limit, ASAT and ALAT ≤ 3 time the&#xD;
             Upper Normal Limit&#xD;
&#xD;
          -  No Renal insufficiency (serum creatinine &lt; 1,5 time the normal limit, creatinine&#xD;
             clearance &gt; 80 mL/min). calculated with MDRD method&#xD;
&#xD;
          -  Hematology function: PNN ≥ 1,5x10⁹/L, platelets ≥ 100x10⁹/L&#xD;
&#xD;
          -  No contraindication to general anaesthesia for heavy surgery&#xD;
&#xD;
          -  Patients having read, signed and dated Informed consent before any study procedure&#xD;
&#xD;
          -  Childbearing patients have to take appropriate contraceptive methods during the&#xD;
             treatment and until 6 months after the treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient age &lt;18 years&#xD;
&#xD;
          -  Previous cancer in the last 5 years (except cutaneous baso-cellular epithelioma or&#xD;
             uterine peripheral epithelioma)&#xD;
&#xD;
          -  Hypersensitivity to Platinum compound&#xD;
&#xD;
          -  Distant metastasis&#xD;
&#xD;
          -  Use of anti-angiogenic treatment&#xD;
&#xD;
          -  Patient with other concurrent severe life threatening disease&#xD;
&#xD;
          -  The need to perform more than two segmental digestive resections during the CRS +/-&#xD;
             HIPEC surgery&#xD;
&#xD;
          -  Any progressive disease during the IV systemic second-line chemotherapy&#xD;
             (platine-based)&#xD;
&#xD;
          -  Incomplete cytoreductive surgery with macroscopical residual disease (Sugarbaker &gt;&#xD;
             CC1)&#xD;
&#xD;
          -  Early relapse: less than 6 mois after the end of the first treatment&#xD;
&#xD;
          -  Ovarian tumor other than Epithelioma Ovarian Cancer&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Patients with any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  Clinically significant cardiovascular disease contraindicating the hyper hydratation,&#xD;
             which is necessary for HIPEC&#xD;
&#xD;
          -  Patient already treated with HIPEC for the ovarian cancer&#xD;
&#xD;
          -  Individual deprived of liberty or placed under the authority of a tutor&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc CLASSE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre rené Gauducheau, NANTES</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'AMIENS</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Kéraudren</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pôle Santé Sud</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hopsitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM - Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Saint Etienne- Hopital Nord</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ico-Centre Rene Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006 Mar;13(3):405-12. Epub 2006 Jan 30.</citation>
    <PMID>16485159</PMID>
  </results_reference>
  <results_reference>
    <citation>Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43.</citation>
    <PMID>16394300</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

